• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冠心病和其他心血管病的一级预防:重点综述。

Primary Prevention of Coronary and Other Cardiovascular Diseases: A Focused Review.

机构信息

Department of Hygiene, Wakayama Medical University.

Department of Cardiology, Keio University School of Medicine, Keio University.

出版信息

J Atheroscler Thromb. 2024 Aug 1;31(8):1113-1128. doi: 10.5551/jat.RV22019. Epub 2024 Jun 1.

DOI:10.5551/jat.RV22019
PMID:38825504
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11300672/
Abstract

In 2022, the Japan Atherosclerosis Society (JAS) updated its prevention guidelines, the "Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022" (JAS2022GL), expanding its scope from coronary artery disease (CAD) to atherosclerotic cardiovascular diseases (ASCVDs), including atherothrombotic stroke. The following year, the Japanese Circulation Society (JCS) updated its guidelines for primary prevention entitled "JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease" (JCS2023GL). Since those publications, scientific advancements in relevant fields have continued. This review article outlines the current recommendations provided by the guidelines, provides background information supporting these recommendations, introduces scientific findings subsequent to prior publications, and discusses future directions on select topics for the primary prevention of CVD. The topics covered in this review are traditional risk factors, including dyslipidemia and hypertension, the application of comprehensive risk stratification or risk scoring systems, patient-specific topics, salt and alcohol, and environmental factors. These topics were deliberate and selected by the authors, who were involved in the compilation of either or both JAS2022GL and JCS2023GL. This review not only emphasizes the pivotal role of continuously updated guidelines in shaping clinical practice but also stresses the urgent need for ongoing research to bridge existing knowledge and practice gaps.

摘要

2022 年,日本动脉硬化学会(JAS)更新了其预防指南,即“日本动脉硬化学会(JAS)2022 年动脉粥样硬化性心血管疾病预防指南”(JAS2022GL),将其范围从冠状动脉疾病(CAD)扩大到动脉粥样硬化性心血管疾病(ASCVDs),包括血栓性卒中。次年,日本循环学会(JCS)更新了其题为“JCS 2023 冠状动脉疾病一级预防指南”(JCS2023GL)的一级预防指南。自这些出版物发布以来,相关领域的科学进展仍在继续。本文概述了指南提供的当前建议,提供了支持这些建议的背景信息,介绍了先前出版物后的科学发现,并就 CVD 一级预防的一些选定主题讨论了未来方向。本文涵盖的主题是传统风险因素,包括血脂异常和高血压,综合风险分层或风险评分系统的应用,患者特定主题,盐和酒精,以及环境因素。这些主题是由作者精心挑选的,他们参与了 JAS2022GL 和 JCS2023GL 的编写。本综述不仅强调了不断更新的指南在塑造临床实践方面的关键作用,还强调了迫切需要开展研究,以弥合现有知识和实践之间的差距。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb2/11300672/7881f52d4c9c/31_RV22019_3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb2/11300672/b6c96cae03a4/31_RV22019_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb2/11300672/08aeb3ccbd17/31_RV22019_2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb2/11300672/7881f52d4c9c/31_RV22019_3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb2/11300672/b6c96cae03a4/31_RV22019_1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb2/11300672/08aeb3ccbd17/31_RV22019_2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cb2/11300672/7881f52d4c9c/31_RV22019_3.jpg

相似文献

1
Primary Prevention of Coronary and Other Cardiovascular Diseases: A Focused Review.冠心病和其他心血管病的一级预防:重点综述。
J Atheroscler Thromb. 2024 Aug 1;31(8):1113-1128. doi: 10.5551/jat.RV22019. Epub 2024 Jun 1.
2
Major Global Coronary Artery Calcium Guidelines.主要全球冠状动脉钙化指南。
JACC Cardiovasc Imaging. 2023 Jan;16(1):98-117. doi: 10.1016/j.jcmg.2022.06.018. Epub 2022 Sep 14.
3
[Present Execution of and Problems with Clinical Lipid Examination and Application of "the Japan Atherosclerotic Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012"].["日本动脉粥样硬化协会(JAS)2012年动脉粥样硬化性心血管疾病预防指南的临床血脂检查实施情况及问题与应用"]
Rinsho Byori. 2014 Sep;62(9):884-91.
4
[Essence of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version and Treatment Guide for Dyslipidemia 2013--Current Strategy for the Lipid Assessment].[日本动脉粥样硬化协会(JAS)日本动脉粥样硬化性心血管疾病诊断与预防指南2012版及血脂异常治疗指南2013——血脂评估的当前策略]
Rinsho Byori. 2014 Sep;62(9):878-83.
5
Coronary artery disease. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012 version.冠状动脉疾病。日本动脉粥样硬化协会(JAS)日本动脉粥样硬化性心血管疾病诊断与预防指南——2012版执行摘要。
J Atheroscler Thromb. 2014;21(2):86-92. doi: 10.5551/jat.19158. Epub 2013 Dec 10.
6
Multicentre, open-label, randomised controlled clinical trial to assess the efficacy and safety of appropriate target values for lipid management in patients who have mild-to-moderate stenotic lesions with high-risk plaques in coronary arteries: study protocol.多中心、开放标签、随机对照临床试验,评估在冠状动脉存在高危斑块的轻中度狭窄病变患者中进行血脂管理的合适目标值的疗效和安全性:研究方案。
BMJ Open. 2019 Jan 25;9(1):e022843. doi: 10.1136/bmjopen-2018-022843.
7
CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.CAC 评分提高了 ESC 和 AHA/ACC 一级预防指南中他汀类药物适应证的冠状动脉和心血管风险评估。
JACC Cardiovasc Imaging. 2017 Feb;10(2):143-153. doi: 10.1016/j.jcmg.2016.03.022. Epub 2016 Sep 21.
8
Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -- 2012.预防心血管疾病的综合风险管理:日本动脉粥样硬化协会(JAS)日本动脉粥样硬化性心血管疾病诊断与预防指南——2012年执行摘要
J Atheroscler Thromb. 2013;20(7):603-15. doi: 10.5551/jat.15867. Epub 2013 Jul 25.
9
Women. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan―2012 Version.女性。日本动脉粥样硬化协会(JAS)日本动脉粥样硬化性心血管疾病诊断与预防指南——2012版执行摘要。
J Atheroscler Thromb. 2014;21(4):291-5. doi: 10.5551/jat.19711. Epub 2013 Dec 10.
10
Carotid intima-media thickness and plaque in apparently healthy Japanese individuals with an estimated 10-year absolute risk of CAD death according to the Japan Atherosclerosis Society (JAS) guidelines 2012: the Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA).根据日本动脉硬化学会(JAS)2012 指南,评估 10 年 CAD 死亡绝对风险的日本健康个体的颈动脉内膜中层厚度和斑块:滋贺县亚临床动脉粥样硬化的流行病学研究(SESSA)。
J Atheroscler Thromb. 2013;20(10):755-66. doi: 10.5551/jat.17244. Epub 2013 Jul 5.

引用本文的文献

1
Beyond Cholesterol: Emerging Risk Factors in Atherosclerosis.超越胆固醇:动脉粥样硬化中的新兴风险因素。
J Clin Med. 2025 Mar 29;14(7):2352. doi: 10.3390/jcm14072352.
2
Involvement of Megasphaera in the oral microbiome and dyslipidemia onset: evidence from a community-based study in Japan.巨球形菌在口腔微生物群与血脂异常发病中的作用:来自日本一项基于社区研究的证据。
Folia Microbiol (Praha). 2025 Apr 2. doi: 10.1007/s12223-025-01258-4.

本文引用的文献

1
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease.《日本循环学会2023年冠状动脉疾病一级预防指南》
Circ J. 2024 Apr 25;88(5):763-842. doi: 10.1253/circj.CJ-23-0285. Epub 2024 Mar 13.
2
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.日本动脉粥样硬化协会(JAS)2022年动脉粥样硬化性心血管疾病预防指南。
J Atheroscler Thromb. 2024 Jun 1;31(6):641-853. doi: 10.5551/jat.GL2022. Epub 2023 Dec 19.
3
Blood Pressure Effect of Traffic-Related Air Pollution : A Crossover Trial of In-Vehicle Filtration.
交通相关空气污染对血压的影响:车载过滤的交叉试验。
Ann Intern Med. 2023 Dec;176(12):1586-1594. doi: 10.7326/M23-1309. Epub 2023 Nov 28.
4
Projected Change in the Burden of Excess Cardiovascular Deaths Associated With Extreme Heat by Midcentury (2036-2065) in the Contiguous United States.到本世纪中叶(2036-2065 年),与极端高温相关的美国本土心血管疾病超额死亡负担的预计变化。
Circulation. 2023 Nov 14;148(20):1559-1569. doi: 10.1161/CIRCULATIONAHA.123.066017. Epub 2023 Oct 30.
5
Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial).他汀类药物延长老年人无残疾生存时间和一级预防心血管事件的效果:初级保健中一项随机对照试验的方案(STAREE 试验)。
BMJ Open. 2023 Apr 3;13(4):e069915. doi: 10.1136/bmjopen-2022-069915.
6
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?重新思考更年期激素治疗:针对谁、什么、何时以及多长时间?
Circulation. 2023 Feb 14;147(7):597-610. doi: 10.1161/CIRCULATIONAHA.122.061559. Epub 2023 Feb 13.
7
Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial.强化降压治疗降低血管事件风险的原理和设计(ESPRIT):一项多中心开放标签随机对照试验。
Am Heart J. 2023 Mar;257:93-102. doi: 10.1016/j.ahj.2022.12.003. Epub 2022 Dec 7.
8
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.依洛西仑和心血管事件:III 期临床试验的患者水平分析。
Eur Heart J. 2023 Jan 7;44(2):129-138. doi: 10.1093/eurheartj/ehac594.
9
Treatment and Prevention of Heat-Related Illness.与热相关疾病的治疗与预防
N Engl J Med. 2022 Oct 13;387(15):1404-1413. doi: 10.1056/NEJMcp2210623. Epub 2022 Sep 28.
10
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.他汀类药物用于成年人的心血管疾病一级预防:美国预防服务工作组推荐声明。
JAMA. 2022 Aug 23;328(8):746-753. doi: 10.1001/jama.2022.13044.